Bioventus Secures FDA Clearance for Two Next-Generation Peripheral Nerve Stimulation Devices
核心洞察
Bioventus Inc. (搜索) received FDA 510(k) clearances for TalisMann (搜索)™ and StimTrial (搜索)™, expanding its peripheral nerve stimulation portfolio for chronic pain (搜索) management.
The clearances position the company to capitalize on the rapidly growing PNS market, estimated to exceed $500 million by 2029 with annual growth above 20 percent.
TalisMann (搜索)™ features patented electric field conduction technology designed to reach deeper nerves and provide long-term chronic pain (搜索) relief.
Bioventus Inc. (搜索) announced a significant regulatory milestone with the U.S. Food and Drug Administration's 510(k) clearances for both TalisMann (搜索)™ and StimTrial (搜索)™, two next-generation peripheral nerve stimulation (PNS) devices designed for chronic pain (搜索) management. The clearances expand the company's innovative portfolio of non-opioid, minimally invasive therapies and position Bioventus to capture growth in the rapidly expanding PNS market.
Market Opportunity and Strategic Impact
The FDA clearances represent a substantial growth opportunity for Bioventus as the company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann (搜索)™ and StimTrial (搜索)™ now FDA-cleared, Bioventus offers a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility.
"The FDA clearance of both TalisMann (搜索)™ and StimTrial (搜索)™ represents a significant step forward in our PNS business, providing patients with innovative technologies. It also creates an exciting growth opportunity for our business," said Anthony Doyle, General Manager, Pain and Restorative Therapies of Bioventus.
Device Technologies and Clinical Applications
TalisMann™ Advanced Stimulation System
TalisMann (搜索)™ combines Bioventus' patented electric field conduction technology with an integrated pulse generator to potentially reach deeper, larger nerves. This combination is designed to provide long-term relief from chronic nerve pain (搜索) for patients, potentially increasing the number of patients who respond to neuromodulation therapy. From a physician's perspective, the increase in power allows for easier lead placement and potentially broadens addressable nerves.
StimTrial™ Evaluation Platform
StimTrial (搜索)™ represents Bioventus' first trial lead, providing physicians the ability to evaluate patient response to PNS therapy. The company expects this capability will facilitate physician adoption and payer reimbursement where trial assessments are required, addressing a critical need in the clinical workflow for PNS therapy implementation.
Commercial Launch Timeline
Bioventus expects to begin a limited commercial release of both TalisMann (搜索)™ and StimTrial (搜索)™ in select U.S. markets during the third quarter of 2025, with a broader rollout planned for early 2026. This phased approach allows the company to gather initial market feedback and optimize its commercial strategy before full-scale deployment.
Addressing Clinical Needs
The development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs. The comprehensive PNS portfolio enables physicians to potentially treat patients across the entire care continuum, from initial assessment through long-term therapy management, providing greater flexibility in treatment approaches for chronic pain (搜索) conditions.